Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VA2914 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| VA2914 | DRUG | - |
Inclusion Criteria: * women in good general health with regular, ovulatory menstrual cycles * age 18-35 * not pregnant * not sexually active or reliably use barrier methods of contraception * normal liver and renal functions and normal laboratory exams Exclusion Criteria: * pregnant or breastfeed...
VA2914 is being developed for contraception. It is a small molecule in the endocrine therapeutic area and has been studied in a Phase 2 trial that enrolled 48 healthy female volunteers aged 18 years and older in Belgium and France. The trial evaluated low dose continuous administration of VA2914.
VA2914 is being developed by Perrigo Company plc, which trades under the ticker PRGO. The company is the sponsor of the Phase 2 clinical program for this contraceptive candidate.
VA2914 is in Phase 2 clinical development. One Phase 2 trial has been completed, and there are currently no active trials listed for this drug. It is an investigational product and has not been approved by the FDA.
VA2914 has been studied in one completed Phase 2 trial, NCT00456924, titled Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914. The trial enrolled 48 participants, was randomized and double blind, and took place in Belgium and France.